A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is application/pdf
.
Prognostic gene signatures for non-small-cell lung cancer
2009
Proceedings of the National Academy of Sciences of the United States of America
Resectable non-small-cell lung cancer (NSCLC) patients have poor prognosis, with 30 -50% relapsing within 5 years. Current staging criteria do not fully capture the complexity of this disease. Survival could be improved by identification of those early-stage patients who are most likely to benefit from adjuvant therapy. Molecular classification by using mRNA expression profiles has led to multiple, poorly overlapping signatures. We hypothesized that differing statistical methodologies
doi:10.1073/pnas.0809444106
pmid:19196983
pmcid:PMC2636731
fatcat:f6m5h4f52fc5vcbslzex6otqzi